We previously reported the parental anti-CD6 mAb used in the CD6-ADC development is effective in treating mouse models of autoimmune diseases such as MS (11) and rheumatoid arthritis (RA) (12) by suppressing T cell responses without depleting the CD6+ T cells. Here, CD6 is linked to myeloid sarcoma.